On November 19, 2026, MSD and Isomorphic Labs announced a research collaboration to discover small-molecule candidates for one unnamed oncology target. Isomorphic Labs will make computational predictions and molecular designs using its IsoDDE engine and selected MSD datasets; MSD will lead preclinical and clinical development and handle manufacturing and commercialization of any resulting product, according to the company-issued announcement. The announcement describes candidate-discovery research, not a treatment result.
For background on the company’s earlier financing, see NeoTeo’s coverage of Isomorphic Labs’ Series C; the MSD agreement concerns a separate research collaboration.
What the partnership covers
The program aims to identify potential small-molecule medicines against a single oncology target. Isomorphic Labs will use its drug-design engine, IsoDDE, and selected data from MSD to generate computational predictions and molecular designs. The target is not named in the announcement.
How the companies divide the work
Isomorphic Labs is responsible for the computational design work. MSD supplies selected data and is assigned the later stages: preclinical and clinical development, followed by manufacturing and commercialization if the research yields a product. The announcement reports no drug candidate, experimental result or clinical outcome.
Computational design is one stage of the program; MSD is responsible for preclinical and clinical development.
How the agreement structures payments
The announced terms include an upfront payment, potential milestone payments tied to research, development, regulatory and commercial events, and tiered royalties on net sales. Isomorphic Labs may choose to co-fund development in exchange for higher royalties.